



Cite this: *RSC Adv.*, 2019, 9, 32017

Highly stereoselective gram scale synthesis of all the four diastereoisomers of Boc-protected 4-methylproline carboxylates†

Kehuan Sun,^{‡ac} Cheng Tao,^{‡bcd} Bohua Long,^{id *cd} Xiaobin Zeng,^{id *e} Zhengzhi Wu^{*cd} and Ronghua Zhang^{*a}

Received 28th August 2019
 Accepted 29th September 2019

DOI: 10.1039/c9ra06827a

rsc.li/rsc-advances

A general and practical synthetic process for all the four diastereoisomers of Boc-protected 4-methylproline carboxylates has been developed with essentially complete stereoselectivity on the gram scale, which represents the most diastereoselective preparation of 4-methylproline derivatives to date. This synthesis features an Evans asymmetric alkylation to elegantly establish the challenging stereochemistry of the 4-methyl group, providing valuable insights for the diastereoselective preparation of 4-substituted prolines.

4-Methylprolines (Fig. 1) are one of the most important structural motifs found in numerous natural products and biologically active compounds. For example, (2*S*,4*S*)-4-methylproline (1) is the crucial component of the dimerized pentapeptides nazumazoles A–C which have been found to exhibit potential cytotoxicity against P388 murine leukemia cells;¹ the *trans*-isomers (2 and 4) are valuable precursors of various natural compounds, such as methylgriselimycin,^{2a} monamycin D₁,^{2b} and cyclopeptide FR235222;³ furthermore, (2*R*,4*R*)-4-methylproline (3) has found wide application in therapeutic agents such as the N¹⁴-desacetoxytubulyisin analogue with potential applications in clinics.⁴ In this regard, development of a general and highly diastereoselective route to 4-methylprolines would greatly facilitate the synthesis of various relevant natural products and medicines. We wish to develop a general and practical synthetic process of all the four diastereoisomers of 4-methylprolines for our long-term efforts on the total synthesis of nazumazoles A–C and other 4-methylproline-containing bioactive compounds.

During the last few decades, several strategies have been employed to the diastereoselective preparation of 4-methylprolines. In 1991, Beaulieu and co-workers reported the synthesis

of Boc-protected 4-methyl proline carboxylates by utilizing the intramolecular radical cyclization approach.⁵ In 2003, Goodman and co-workers realized the diastereoselective synthesis of Boc-protected 4-methyl prolines employing a divergent asymmetric hydrogenation strategy.⁶ In 2010, Willis and co-workers developed a chemoenzymatic route toward the 4-methylprolines by taking advantage of two biotransformations to establish the absolute configuration.⁷ However, most of these methods suffer from the poor control of the stereochemistry of the 4-methyl group and often use expensive catalysts or toxic reagents. Furthermore, the harsh conditions




Fig. 1 Selective relevant natural products and bioactive compounds containing 4-methylprolines (1–4).

^aCollege of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, China

^bIntegrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou 510632, China

^cThe First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China. E-mail: bhlong121@163.com

^dShenzhen Institute of Geriatric Medicine, Shenzhen, 518035, China

^eCentral Center Lab of Longhua Branch, Department of Infectious Disease, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen 518120, Guangdong Province, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9ra06827a

‡ These authors contributed equally to this work.




coupled with expensive reagent cost would impede the application of the current methods to multigram-scale production.

From a viewpoint of synthetic application, the Boc-protected carboxylate form of 4-methylprolines (**8**, **8'**, *ent*-**8** and *ent*-**8'**) were more practical and operationally simple than 4-methylprolines (**1**–**4**), because the Boc-protected 4-methylproline carboxylates can be easily purified and stored, and they also can be further elaborated to 4-methylprolines (**1**–**4**) and other valuable intermediates according to literature procedure.⁸

As part of our long-term efforts on the total synthesis of nazumazoles A–C and other 4-methylproline-containing bioactive compounds, we present herein a general and practical synthetic process for all the four diastereoisomers of Boc-protected 4-methylproline carboxylates with essentially complete stereoselectivity on gram scale (Scheme 1).

We envisaged that the main synthetic challenge of 4-methylprolines is that of exercising control of the absolute configuration at C4, and this vexing problem could be addressed by employing the asymmetric alkylation approach developed by Evans.⁹ With this idea in mind, we start our retrosynthetic analysis. As the retrosynthetic analysis strategy was also suit for other three diastereoisomers, we just take one isomer as an example (Scheme 2).


As for the Boc-protected (*2S,4S*)-4-methylproline carboxylate (**8**), the C2 stereocenter would be introduced *via* an intramolecular S_N2 reaction of amine **9**. The C4 stereocenter could be installed by utilizing the asymmetric alkylation reaction, which traced the origin of amine **9** to Evans' chiral auxiliary **6**. The




Scheme 2 Retrosynthetic analysis.

Evans' chiral auxiliary **6** could be easily prepared from the cheap commercial chiral glutamic acid. In such case, choosing the different chiral glutamic acid (*D*-glutamic acid or *L*-glutamic acid) and different chiral *N*-acyloxazolidinone auxiliaries (*S*-4-benzyl-2-oxazolidinone or *R*-4-benzyl-2-oxazolidinone) would control the configuration of the generated stereogenic center at C4. As such, this would provide a general and facile synthetic protocol for all the four diastereoisomers of 4-methylprolines.

Our strategy for rapid access to the Evans' chiral auxiliary **6** commenced with the chiral *D*-glutamic acid (**5**) (Scheme 3). Compound **10** was prepared from *D*-glutamic acid *via* a known two-step process¹⁰ in 80% yield. Then a chemoselective reduction of the ester group adjacent to the hydroxyl group was achieved with borane-dimethyl sulfide complex to afford diol **11** in 90% yield.¹¹ Then protection of diol **11** followed by hydrolysis of the methyl ester with lithium hydroxide gave acid **12**, which was directly coupled with chiral (*S*)-oxazolidinone auxiliary in the presence of pivaloyl chloride and triethyl amine to afford Evans' chiral auxiliary **6** (72% yield, three steps).



Scheme 3 Establishment of the C4 stereochemistry.



Scheme 1 Diastereoselective synthesis of the 4-methylproline derivatives.




With the Evans' chiral auxiliary **6** in hand, the crucial asymmetric alkylation was then explored. The methylation proceeded successfully when using NaHMDS as the base followed by treatment with MeI to give desired product **7** in 70% yield. Gratifyingly, the desired product **7** was obtained as a single stereoisomer on a 40 g scale. As such, the C4 configuration was established with essentially complete stereoselectivity. As we haven't observed and isolated any isomers of **7** in this reaction, the 70% yield may be caused by certain unknown non-isomeric byproducts of unwanted side-reactions, which is common in the Evans' methylation reactions.⁹

With the access to C4 configuration realized, we next turned our attention to establishment of the requisite C2 stereocenter and the completion of the diastereoselective synthesis of Boc-protected 4-methylproline carboxylates.

As shown in Scheme 4, reductive cleavage of the Evans auxiliary by utilizing sodium borohydride generated alcohol **13** in 90% yield.¹² Then the hydroxyl group in compound **13** was directly transformed into the azido group by treatment with DPPA and DBU in dry toluene under reflux condition in 85% isolated yield along with 10% recovered starting material. Much to our delight, when xylene was used as solvent, the azide **14** was forged in 92% yield.

With the azide **14** in hand, selective cleavage of the primary TBS-ether was then explored. A variety of traditional methods including CSA/MeOH,¹³ TsOH/MeOH,¹⁴ and conc. HCl/CHCl₃ (ref. 15) were examined, and many of our efforts were fruitless, leading to incomplete conversion or deprotection of the two TBS-ether. In contrast, treatment of **14** with NH₄F (50 eq.) in MeOH at room temperature for 6 h provided the desired primary alcohol **15** in 75% yield. Unfortunately, oxidation of the resulting hydroxyl group to carboxylic acid with NaIO₄ in the presence of catalytic amounts of RuCl₃ (ref. 16) was not achieved, leading to decomposition of the starting material.




Scheme 4 Synthesis of the Boc-protected (2*S*,4*S*)-4-methylproline carboxylate.

Therefore, the transformation was operated in a two-step process. Alcohol **15** was initially subjected to oxidation with IBX in DMSO at 30 °C, and the resulting aldehyde **16** was subsequently transformed into the corresponding methyl ester **17** by adding NIS and potassium carbonate in MeOH at room temperature¹⁷ in 90% overall yield. However, considering NIS was an expensive reagent, we were not satisfied with the result and were eager to find a more cheap procedure for the preparation of compound **17** to make it more accessible. Gratifyingly, when aldehyde **16** was further oxidized with KOH/I₂/MeOH system,¹⁸ the desired methyl ester **17** was easily and economically synthesized under the mild condition (95% yield, two steps, 13 g scale).

Then TBS ether **17** was deprotected with CSA to afford the corresponding alcohol **18**. Tosylation of alcohol **18** was carried out with *p*-toluenesulfonyl chloride in the presence of base such as pyridine, Et₃N or DMAP, leading to less than 50% yield. Fortunately, the yield was significantly increased to 90% when DABCO (2.0 eq.) was used as the base.¹⁹

Finally, the two-step azide reduction/intramolecular S_N2 cyclization procedure was performed as a tandem one-pot process successfully under the hydrogenation condition. Then the resulting cyclization product was directly protected as its Boc derivative by adding NaHCO₃ and Boc₂O to afford the desired Boc-protected (2*S*,4*S*)-4-methylproline carboxylate (**8**) in 90% yield. It should be noted that, the present turned out to be very practical, and the desired product (**8**) can be routinely prepared on a 8.5 g scale with full stereochemical control. The conversion of **8** into (2*S*,4*S*)-4-methylproline (**1**) has been previously reported.⁸

As shown in Scheme 5, we then accomplished the gram-scale synthesis of the other three diastereoisomers **8'** (15 steps, 13%), *ent*-**8** (15 steps, 12%), *ent*-**8'** (15 steps, 17%) by utilizing the same strategy described above. Because a large amount of **8** was



Scheme 5 Gram scale synthesis of the other three diastereoisomers of Boc-protected 4-methylproline carboxylates.



needed for our current program on the total synthesis of nazumazoles A–C, **8** was prepared on a 8.5 g scale (15 steps, 17%). We thought that obtaining the other three isomers in gram scale was enough to illustrate the high synthetic practicality of the present route, so we haven't attempted bigger quantities of the other three isomers. In the key Evan's methylation reactions,⁹ the desired methylation products 7', *ent*-7, *ent*-7' were obtained in yields of 66%, 73%, 73%, respectively and without any isomeric methylation products observed, which highlights the essentially complete selectivity of our route. For experimental details, see ESI.†

Conclusions

In conclusion, a general and practical synthetic route for all the four diastereoisomers of Boc-protected 4-methylproline carboxylates has been developed with essentially complete stereoselectivity on gram scale. To the best of our knowledge, our present route represents the most diastereoselective preparation of 4-methylproline derivatives to date. Other features of the synthesis include the accessibility of simple starting materials, cheap synthetic cost, and mild reaction conditions, all of which highlight the high synthetic practicality of the present route. This concise strategy offers a general and facile synthetic protocol for chiral 4-methylprolines and 4-substituted prolines. On the basis of the current work, the investigation of the dimerized pentapeptides nazumazoles A–C and other complex natural products containing 4-methylprolines is ongoing in the laboratory.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We thank the Health and Family Planning Commission of Shenzhen Municipality (201601053), Shenzhen Science and Technology Program (JCYJ20160428110124165, JCYJ20160428110235852, JCYJ20170413161352000), NSFC (81673837, 81574038), Guangdong Science and Technology Program (2016A020226039, 2015B020211001), and Sanming Project of Medicine in Shenzhen (SZSM201612049) for financial support.

Notes and references

1 K. Fukuhara, K. Takada, S. Okada and S. Matsunaga, *Org. Lett.*, 2015, **17**, 2646.

- 2 (a) P. Lukat, Y. Katsuyama, S. Wenzel, T. Binz, C. König, W. Blankenfeldt, M. Brönstrup and R. Müller, *Chem. Sci.*, 2013, **1**; (b) H. J. Hale, N. Jogiya and S. Manaviyar, *Tetrahedron Lett.*, 1998, **39**, 7163.
- 3 W. Xie, B. Zou, D. Pei and D. Ma, *Org. Lett.*, 2005, **7**, 2775.
- 4 D. Toader, F. Wang, L. Gingipalli, M. Vasbinder, M. Roth, S. Mao, M. Block, J. Harper, S. Thota, M. Su, J. Ma, V. Bedian and A. Kamal, *J. Med. Chem.*, 2016, **59**, 10781.
- 5 F. Soucy, D. Wernic and P. Beaulieu, *J. Chem. Soc., Perkin Trans. 1*, 1991, 2885.
- 6 J. R. Del Valle and M. Goodman, *J. Org. Chem.*, 2003, **68**, 3923.
- 7 S. R. Crosby, R. B. Sessions and C. L. Willis, *Synlett*, 2010, **4**, 539.
- 8 (a) X. Gao, Y. Liu, S. Kwong, Z. Xu and T. Ye, *Org. Lett.*, 2010, **12**, 3018; (b) J. Goodreid, E. Silveira dos Santos and R. Batey, *Org. Lett.*, 2015, **17**, 2182.
- 9 (a) D. A. Evans, M. D. Ennis and D. J. Mathre, *J. Am. Chem. Soc.*, 1982, **104**, 1737; (b) M. Heravi, V. Zadsirjan and B. Farajpour, *RSC Adv.*, 2016, **6**, 30498; (c) Y. Lu and P. W. Schiller, *Synthesis*, 2001, **11**, 1639; (d) S. Das and R. K. Goswami, *J. Org. Chem.*, 2014, **79**, 9778; (e) S. Guchhait, S. Chatterjee, R. S. Ampapathi and R. K. Goswami, *J. Org. Chem.*, 2017, **82**, 2414.
- 10 Y. Geng, M. Zheng, J. Li, D. Zou, Y. Wu and Y. Wu, *Tetrahedron Lett.*, 2017, **58**, 3966.
- 11 M. Fox, M. Jackson, I. C. Lennon and R. McCague, *J. Org. Chem.*, 2005, **70**, 1227.
- 12 M. Prashad, D. Har, H. Y. Kim and O. Repic, *Tetrahedron Lett.*, 1998, **39**, 7067.
- 13 R. S. Ghogare, S. B. Wadavrao and A. V. Narsaiah, *Helv. Chim. Acta*, 2016, **99**, 247.
- 14 P. V. Ramachandran, A. Srivastava and D. Hazra, *Org. Lett.*, 2007, **9**, 157.
- 15 S. Tripathy and A. Chattopadhyay, *Tetrahedron: Asymmetry*, 2012, **23**, 1423.
- 16 B. Long, S. Tang, L. Chen, S. Qu, B. Chen, J. Liu, A. R. Maguire, Z. Wang, Y. Liu, H. Zhang, Z. Xu and T. Ye, *Chem. Commun.*, 2013, **49**, 2977.
- 17 C. McDonald, H. Holcomb, K. Kennedy, E. Kirkpatrick, T. Leathers and P. Vanemon, *J. Org. Chem.*, 1989, **54**, 1213.
- 18 S. Yamada, D. Morizono and K. Yamamoto, *Tetrahedron Lett.*, 1992, **33**, 4329.
- 19 J. Hartung, S. Hünig, R. Kneuer, M. Schwarz and H. Wenner, *Synthesis*, 1997, 1433.

